Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    V81444
Previous Study | Return to List | Next Study

A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02764892
Recruitment Status : Completed
First Posted : May 6, 2016
Last Update Posted : May 6, 2016
Sponsor:
Information provided by (Responsible Party):
Vernalis (R&D) Ltd

Brief Summary:
The main purpose of the study is to identify the best dose of V81444 to use in future trials in patients with Parkinson's disease. The study will also explore the effects of V81444 on brain activity and blood flow with tests of mental ability ("cognitive function tests"). It will also check how safe V81444 is and how well it is tolerated after dosing.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: V81444 Phase 1

Detailed Description:

In this Phase I, single-centre, open-label, adaptive, single-dose study at multiple dose levels, the relationship between dose and plasma concentration of orally administered V81444 to brain A2A RO was investigated in 6 healthy male volunteers. In addition, the effects of V81444 on regional brain activity and perfusion during tests of cognitive function, and the safety and tolerability of V81444 were assessed. For each subject, the study consisted of a screening visit, a baseline visit, a treatment period, and a safety follow-up visit. The dose of V81444 and timing of scans performed were defined in the protocol for the first 2 subjects only. The dose, nature and timings of assessments for subsequent subjects were determined based on review of emerging receptor binding, pharmacokinetic (PK), pharmacodynamic (PD) and safety information.

In each treatment period, subjects were admitted to the unit on the day before dosing (Day -1), received a single oral dose of V81444 on Day 1 and, subject to satisfactory medical review, were discharged a minimum of 12 h after dosing. Overall, 3 doses of V81444 were assessed (250 mg, 50 mg, and 100 mg), with 2 subjects included at each dose level. PD assessments were performed at baseline and after each dose of V81444 using PET (with the A2A radioligand, to measure brain A2A RO, as well as MRI techniques to investigate the effects of V81444 on regional brain activity and perfusion during cognitive function tests. PK parameters were assessed by assay of V81444 concentration in plasma. Safety and tolerability were assessed by monitoring physical examination findings, adverse events (AEs), vital signs, 12 lead electrocardiogram (ECG) and clinical laboratory safety tests.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male Volunteers
Study Start Date : August 2012
Actual Primary Completion Date : November 2012
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: V81444
Single oral dose of V81444
Drug: V81444
Single oral dose of V81444




Primary Outcome Measures :
  1. Plasma concentration V81444 corresponding with 50% brain A2A receptor occupancy. [ Time Frame: Up to 27 hours after a single dose ]
    Plasma concentrations of V81444 and binding of [11C]SCH442416 radioligand to brain A2A receptors using PET before and after V81444 dosing to determine occupancy of A2A receptors by V81444.


Secondary Outcome Measures :
  1. Cognitive function using functional MRI [ Time Frame: 5 hours after dosing ]
  2. Change versus placebo in proportion of subjects with adverse events [ Time Frame: Up to 7 Days after last dose ]
  3. Change versus placebo in proportion of subjects with abnormal laboratory findings [ Time Frame: Up to 7 Days after last dose ]
  4. Change versus placebo in proportion of subjects with clinically significant abnormalities on vital signs [ Time Frame: Up to 7 Days after last dose ]
  5. Change versus placebo in proportion of subjects with clinically significant abnormalities in 12-lead ECG [ Time Frame: Up to 7 Days after last dose ]
  6. Change versus placebo in proportion of subjects with clinically significant abnormalities on physical examination [ Time Frame: Up to 7 Days after last dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteers: aged 25 to 55 years, in good general health as determined by medical history, physical examination and screening investigations, and taking no regular medication.
  • Confirmation to be sought for all volunteers that their general practitioner has provided an acceptable medical history.

Exclusion Criteria:

  • Any significant medical condition or a history of such a condition that the Investigator considers should exclude the subject from the study.

Specific exclusion criteria relate to

  • usual caffeine intake and willingness to abstain from caffeine
  • history or evidence of clinically significant gastro-intestinal disease
  • presence of structural brain abnormality
  • contraindications or cautions for MRI scanning
  • clotting test results
  • exposure to significant levels of ionising radiation in the past

Layout table for additonal information
Responsible Party: Vernalis (R&D) Ltd
ClinicalTrials.gov Identifier: NCT02764892     History of Changes
Other Study ID Numbers: V81444-1PD-02
First Posted: May 6, 2016    Key Record Dates
Last Update Posted: May 6, 2016
Last Verified: May 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases